Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.
The return profile of NCDs is linked to BBL share price subject to minimum IRR of 12%.
New high-tech facility in Biberach offers attractive workplaces for more than 500 scientists
Malaria is a life-threatening parasitic infection that is spread by the bites of mosquitoes carrying the Plasmodium parasite
The USFDA had classified the inspection as "Official Action Indicated" (OAI).
The burden of treating chronic wounds is growing rapidly due to increasing health care costs
Fully equipped labs with 75-member team set-up and made operational in <100 days
SÜDPACK is setting standards in terms of both performance and sustainability
Bayer reported the highest market capitalization growth of 23.1% during Q1 2023
Several late-stage pipeline products have the potential to address some of these unmet needs
Subscribe To Our Newsletter & Stay Updated
